Heparin interference in anti-XA assays for rivaroxaban and apixaban

被引：0
|
作者：
Cutsforth, G. A. [1 ]
Finnegan, K. [2 ]
机构：
[1] Diagnostica Stago Inc, Vernon Hills, NJ USA
[2] SUNY Stony Brook, Stony Brook, NY 11794 USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO117-WED
引用
收藏
页码：795 / 795
页数：1
相关论文
共 50 条
  • [1] Cross-interference of rivaroxaban and enoxaparin on Berichrom anti-Xa heparin and Biophen direct Xa inhibitor assays
    Wong, W. H.
    Kaur, H.
    Tan, C. W.
    Lee, L. H.
    Ng, H. J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 (04) : E63 - E65
  • [2] UTILITY OF APIXABAN OR RIVAROXABAN ANTI-XA LEVELS IN TRANSITIONING PATIENTS TO HEPARIN INFUSIONS
    Huang, Wan-Ting
    Nguyen, Kevin
    Patel, Aakash
    Lerner, Dmitri
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 447 - 447
  • [3] Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays
    Gosselin, R.
    Grant, R. P.
    Adcock, D. M.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 (05) : 505 - 513
  • [4] Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels
    Mithoowani, Siraj
    Moffat, Karen A.
    Gupta, Akash
    Carlino, Stephen A.
    Crowther, Mark A.
    THROMBOSIS RESEARCH, 2022, 215 : 1 - 4
  • [5] Universal anti-Xa assay for rivaroxaban and apixaban plasma concentration
    Studt, Jan-Dirk
    Stein, Philipp
    Hegemann, Inga
    Koch, Karin
    Sangalli-Baruffaldi, Jessica
    Nagler, Michael
    SWISS MEDICAL WEEKLY, 2018, 148 : 37S - 37S
  • [6] Comparison of apixaban and rivaroxaban trough anti-Xa activity.
    Bookstaver, David
    Sparks, Kimberly
    Pybus, Brandon
    Davis, Dustin
    PHARMACOTHERAPY, 2016, 36 (12): : E239 - E239
  • [7] Apixaban and Rivaroxaban Anti-Xa Concentration Utilization in Clinical Practice
    Kim, Ju Hee
    Shelat, Nidhi
    Ji, Christine S.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2023, 81 (02) : 165 - 170
  • [8] Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban
    Bookstaver, David A.
    Sparks, Kimberly
    Pybus, Brandon S.
    Davis, Dustin K.
    Marcsisin, Sean R.
    Sousa, Jason C.
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (03) : 251 - 256
  • [9] Use of heparin calibrated anti-Xa assay for apixaban and rivaroxaban measurement in the context of regional telestroke activity
    Delassasseigne, Celine
    Leroux, Clementine
    Renou, Pauline
    Girard, David
    Lafargue, Anne
    Morel, Stephane
    Belotti, Pierre Thomas
    Weinmann, Laurent
    ANNALES DE BIOLOGIE CLINIQUE, 2023, 81 (03) : 269 - 279
  • [10] Discordance between the neutralization profile of apixaban, betrixaban, edoxaban and rivaroxaban in the clotting assays and anti-Xa measurements
    Siddiqui, Fakiha
    Tafur, Alfonso
    Hoppensteadt, Debra
    Jeske, Walter
    Lewis, Bruce
    Fareed, Jawed
    FASEB JOURNAL, 2020, 34
12345